Bio News
Met primary endpoint in phase 2/3 trial and demonstrated equivalence to existing treatment 20% high-concentration formulation shortens infusion time and improves patient convenience
Takeda’s treatment for primary immunodeficiency disease (PID), TAK-881, met its primary endpoint in a phase 2/3 trial and demonstrated 99.67% pharmacokinetic equivalence to the existing treatment. The drug is a 20% concentration subcutaneous immunoglobulin (SCIG) that reduces administration volume by 50% and shortens infusion time compared with HyQvia, the existing 10% product. Based on these results, Takeda plans to submit applications for regulatory approval to authorities in the United States, Europe and Japan in fiscal 2026.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
